the what, why, and how of anti-pd-1/pd-l1 immunotherapy for cancer
Published 4 years ago • 90 plays • Length 0:45Download video MP4
Download video MP3
Similar videos
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
1:16
explaining immunotherapy, pd-l1 and pd-1
-
2:12
cancer immunotherapy | the pd-l1 pathway
-
3:29
pd-l1/pd-1 pathway: a security checkpoint
-
23:02
immunotherapy: moving beyond pd1 and pdl1 inhibitors
-
4:27
understanding immunotherapy for nsclc with pd-1 and pd-l1 biomarkers
-
4:53
the role of immunotherapy in cancer treatment (pd-l1 overview)
-
1:49
immunotherapy and beyond for lung cancer prevention
-
1:02:49
pd-l1/pd-1 cancer immunotherapy and new targets - gordon freeman, phd
-
36:47
the status of pd-l1 testing and what is next? | presented by dr. ming tsao
-
1:33:59
revisiting pd-l1 as an immunotherapy biomarker across the cancer spectrum
-
7:37
combining immunotherapies: inhibiting the ctla-4 and pd-1 pathways
-
6:56
all you need to know about pd-l1 by immunohistochemistry
-
3:16
what is pd1 and pdl1 in kidney cancer?
-
15:11
understanding cancer immunotherapy
-
40:33
challenges to precision medicine for anti-cancer immunotherapy
-
50:03
arlene sharpe: roles of the pd-1 pathway in controlling tolerance & tumor immunity
-
3:02
immunotherapy for cancer: what it is and why it’s used
-
8:05
how does pd-l1 score affect treatment options? - lung cancer onctalk 2022